...
首页> 外文期刊>Biopreservation and biobanking >Individual Investigator Profiles of Biospecimen Use in Cancer Research
【24h】

Individual Investigator Profiles of Biospecimen Use in Cancer Research

机译:癌症研究中生物样本使用的个人研究者资料

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Establishing targets for case accrual is an important component of a strategic plan for a biobank. We have previously assessed overall patterns of biospecimen use in cancer research publications in selected journals. Here we extend this analysis to consider patterns of biospecimen use in relation to cancer research programs developed by individual investigators. Methods: We selected three individual cancer research investigators whose independent research programs began circa 1986, have been characterized by extensive use of human tumor biospecimens, and have primarily involved translational research in the areas of breast, lung, and ovarian cancer. We analyzed biospecimen and data usage in their career publications categorized by numbers, type, and format, and accompanying annotating data in terms of conformance with BRISQ reporting and ethics related criteria. Results: Biospecimens were used in 313/474 (66%) of publications analyzed. The average number of biospecimens used by these research programs increased six-fold from less than 1000 in 2001–2003 to greater than 6000 in 2010–2012, and the average cohort sizes per article also increased from approximately 50 to 200 cases per study over the same period in most biospecimen categories ( p < 0.05). The relative proportions of different formats of biospecimens used has varied significantly and continues to change with the emergence of digital biospecimen derived data. In these three translational research programs, BRISQ elements relating to 'Biobank' categories were significantly less well reported for biospecimens used in publications than data corresponding to 'Clinical chart' categories ( p < 0001). Conclusions: This study shows that overall use of biospecimens in cancer research has increased significantly and that dynamic variation in the relative use of different biospecimen formats has also occurred. This study also confirms our previous findings on patterns of biospecimen use and also those concerning incomplete reporting of relevant data elements that has not improved in the past decade.
机译:背景:建立病例累积目标是生物库战略计划的重要组成部分。我们之前已经评估了某些期刊在癌症研究出版物中使用生物标本的总体模式。在这里,我们将这一分析扩展为考虑与个体研究者制定的癌症研究计划相关的生物样本使用方式。方法:我们选择了三名癌症研究人员,他们的独立研究计划始于1986年,其特点是广泛使用人类肿瘤生物标本,并且主要涉及乳腺癌,肺癌和卵巢癌领域的转化研究。我们分析了其职业出版物中的生物标本和数据使用情况,并按编号,类型和格式分类,并根据BRISQ报告和道德相关标准对随附的注释数据进行了分类。结果:生物标本用于分析的313/474(66%)出版物中。这些研究计划使用的生物样本平均数量从2001-2003年的不到1000例增加到2010-2012年的6000例,增长了六倍,并且每篇文章的平均队列规模也从每项研究的约50例增加到200例。在大多数生物标本类别中为同一时期(p <0.05)。所使用的不同形式生物样本的相对比例已显着变化,并且随着数字生物样本衍生数据的出现而不断变化。在这三个翻译研究计划中,与“临床图表”类别相对应的数据,与出版物中使用的生物标本有关的“生物库”类别的BRISQ元素报道得少得多(p <0001)。结论:这项研究表明,在癌症研究中生物标本的总体使用已显着增加,而且不同生物标本格式的相对使用也发生了动态变化。这项研究还证实了我们先前关于生物样本使用方式的发现,以及有关过去十年中没有改善的有关数据元素报告不完整的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号